

4th October 2021

FIJI KAVA ACHIEVES RECORD QUARTERLY RESULTS

- Record revenue achievement of more than \$420,000 (250% of Q1 FY21, 33% up on Q4 FY22)
- Record cash receipts of more than \$440,000 (800% of Q1 FY21, 40% up on Q4 FY22)
- Growth has been driven by record sales through Coles, first full quarter of sales in Chemist Warehouse and first commercial Speciality Ingredients order in the USA

4 October 2021 Brisbane Australia - Fiji Kava Ltd (ASX: FIJ), an Australian-Fijian medicinal kava company which produces natural 'noble kava' products to reduce anxiety, promote relaxation and improve sleep.

Its Noble Kava extract capsules and three Noble Kava varieties of Noble Sleep[™], Noble Calm[™] and Noble Body[™] capsule ranges are sold through Coles and Chemist Warehouse in Australia.

Fiji Kava Instant Kava and Taki Mai Traditional grind drinking kava are also sold in various retail outlets in Fiji and New Zealand as well as in the USA via Amazon and Fijikava.com.

Fiji Kava CEO, Anthony Noble said: "It is extremely pleasing to see Fiji Kava achieve these record quarterly results. The Australian retail environment has been particularly challenging due to Covid-19 lockdowns. Even so, we have seen strong growth in sales via both Coles and Chemist Warehouse. Fiji has begun to reopen, and we have begun to make modest sales into our key retailers there after many months of lockdown.

We were also very pleased with the feedback received via our Specialty Ingredient partner in the USA on the performance of our certified organic kava extract in manufacturing trials. This led to a first commercial order for that market in this quarter. We will continue to work with our partners and our US Directors and Advisory Board to establish our business in the USA in the coming months."

This release has been approved by the Board of Directors

ENDS

For Further Information

For Investors

Jay Stephenson Fiji Kava investors@fijikava.com

For Media

Anthony Noble Fiji Kava anthony@fijikava.com

About Fiji Kava

Fiji Kava Ltd (ASX: FIJ), an Australian-Fijian medicinal kava health & wellness company, producing natural 'noble kava' products for the natural medicine market, estimated to exceed USD \$210 billion by 2026 globally.

As the first foreign company with approval from the Fijian Government to operate in the kava industry. Fiji Kava has established a global leading sustainable and 100% traceable, certified organic supply chain of 'noble kava' including an 111-acre nucleus farm in Levuka, on the island of Ovalau, Fiji.

Fiji Kava is focussed on expanding the availability of noble kava products throughout western markets to provide a natural alternative to prescription medicines to promote sleep, soothe and calm the nerves, support muscle relaxation and relax the mind

Backed by years of independent research, Fiji Kava medical kava products are produced by highquality GMP and are TGA and FDA compliant.

Forward-Looking Statements

This ASX release includes certain forward-looking statements that are based on information and assumptions known to date and are subject to various risks and uncertainties. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Fiji Kava. These factors may cause actual results to differ materially from those expressed in the statements contained in this announcement.